This story has been updated to correct a company mistake. The firm had previously said it would continue marketing its COVID-19 test without FDA authorization.
NEW YORK — Meridian Bioscience said on Tuesday that it has withdrawn its Emergency Use Authorization application to the US Food and Drug Administration for its Revogene SARS-CoV-2 test in order to conduct additional studies on the assay.